



1 SMITHKLINE BEECHAM CORPORATION, d/b/a  
2 GLAXOSMITHKLINE,

No. C 07-05702 CW

3 Plaintiff,

(Docket No. 199)

4 v.

5 ABBOTT LABORATORIES,

6 Defendant.

7  
8 Defendant Abbott Laboratories moves for an order certifying an  
9 interlocutory appeal of three issues:

10 1. Whether Plaintiffs have properly stated a predatory  
11 pricing antitrust claim even though they admittedly  
12 have not satisfied the standard set forth by the  
13 Supreme Court in linkLine, which requires  
allegations of a dangerous probability of recoupment  
and below-cost pricing for the retail product in the  
challenged market?

14 2. Whether Plaintiffs have properly stated a  
15 refusal-to-deal antitrust claim without any actual  
16 refusal to deal in the challenged market, based on  
the allegation that the combined pricing of  
products in two separate markets makes it difficult  
for rivals to compete?

17 3. Whether Plaintiffs can state an antitrust claim  
18 based on a theory that Abbott charged a low (but not  
below-cost) price for Norvir to discourage  
innovation by rivals?

20 Def.'s Mot. at 1. Plaintiffs oppose the motion. The motion was  
21 taken under submission on the papers. Having considered all of the  
22 papers submitted by the parties, the Court DENIES Abbott's motion.

23 BACKGROUND

24 On January 12, 2010, the Court denied Abbott's motion to  
25 dismiss, which was based in large part on John Doe 1 v. Abbott  
Laboratories, 571 F.3d 930 (9th Cir. 2009), and Pacific Bell  
Telephone Co. v. Linkline Communications, Inc., \_\_\_ U.S. \_\_\_, 129  
28 S. Ct. 1109 (2009). In Doe, the Ninth Circuit considered whether,

1 under the Doe plaintiffs' monopoly leveraging theory, Abbott  
2 violated section 2 of the Sherman Act, 15 U.S.C. § 2, through its  
3 conduct in pricing Norvir and Kaletra.<sup>1</sup> 571 F.3d at 932-33. The  
4 court held that the plaintiffs' theory, which did not include  
5 allegations of an antitrust duty to deal or below-cost pricing, was  
6 the "functional equivalent" of the price squeeze theory rejected by  
7 the Supreme Court in Linkline. Id. at 934-35; see also Linkline,  
8 129 S. Ct. at 1114. In Linkline, the Supreme Court addressed  
9 "whether a plaintiff can bring price-squeeze claims under § 2 of  
10 the Sherman Act when the defendant has no antitrust duty to deal  
11 with the plaintiff." 129 S. Ct. at 1116-17. The Court rejected  
12 the plaintiffs' theory, holding that "the price-squeeze  
13 claims . . . are not cognizable under the Sherman Act." Id. at  
14 1123.

15 Here, it is alleged, among other things, that Abbott violated  
16 § 2 by engaging in predatory pricing of a bundled product and by  
17 breaching its antitrust duty to deal. Because Plaintiffs here do  
18 not base their claims on the monopoly leveraging or price squeeze  
19 theories addressed in Doe and Linkline, the Court rejected Abbott's  
20 argument that those cases barred Plaintiffs' antitrust claims. The  
21 Court also rejected Abbott's arguments that Verizon Communications  
22 Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398 (2004),  
23 and MetroNet Services Corp. v. Qwest Corp., 383 F.3d 1124 (9th Cir.  
24 2004), preclude the antitrust duty to deal claims.

25  
26  
27 <sup>1</sup> In Doe, the parties agreed that, as a condition of  
28 settlement, Abbott would take an interlocutory appeal of the  
Court's decisions. 571 F.3d at 932.

## LEGAL STANDARD

2 Pursuant to 28 U.S.C. § 1292(b), a district court may certify  
3 an appeal of an interlocutory order only if three factors are  
4 present. First, the issue to be certified must involve a  
5 "controlling question of law." 28 U.S.C. § 1292(b). Establishing  
6 that a question of law is controlling requires a showing that the  
7 "resolution of the issue on appeal could materially affect the  
8 outcome of litigation in the district court." In re Cement  
9 Antitrust Litig., 673 F.2d 1020, 1026 (9th Cir. 1982) (citing U.S.  
10 Rubber Co. v. Wright, 359 F.2d 784, 785 (9th Cir. 1966)).

11       Second, there must be "substantial ground for difference of  
12 opinion" on the issue. 28 U.S.C. § 1292(b). A substantial ground  
13 for difference of opinion is not established by a party's strong  
14 disagreement with the court's ruling; the party seeking an appeal  
15 must make some greater showing. Mateo v. M/S Kiso, 805 F. Supp.  
16 792, 800 (N.D. Cal. 1992).

17       Third, it must be likely that an interlocutory appeal will  
18 "materially advance the ultimate termination of the litigation."  
19 28 U.S.C. § 1292(b); Mateo, 805 F. Supp. at 800. Whether an appeal  
20 may materially advance termination of the litigation is linked to  
21 whether an issue of law is "controlling" in that the court should  
22 consider the effect of a reversal on the management of the case.  
23 Id. In light of the legislative policy underlying § 1292, an  
24 interlocutory appeal should be certified only when doing so "would  
25 avoid protracted and expensive litigation." In re Cement, 673 F.2d  
26 at 1026; Mateo, 805 F. Supp. at 800. If, in contrast, an  
27 interlocutory appeal would delay resolution of the litigation, it  
28 should not be certified. See Shurance v. Planning Control Int'l.

1 Inc., 839 F.2d 1347, 1348 (9th Cir. 1988) (refusing to hear a  
2 certified appeal in part because the Ninth Circuit's decision might  
3 come after the scheduled trial date).

4 "Section 1292(b) is a departure from the normal rule that only  
5 final judgments are appealable, and therefore must be construed  
6 narrowly." James v. Price Stern Sloan, Inc., 283 F.3d 1064, 1068  
7 n.6 (9th Cir. 2002). Thus, the court should apply the statute's  
8 requirements strictly, and should grant a motion for certification  
9 only when exceptional circumstances warrant it. Coopers & Lybrand  
10 v. Livesay, 437 U.S. 463, 475 (1978). The party seeking  
11 certification of an interlocutory order has the burden of  
12 establishing the existence of such exceptional circumstances. Id.  
13 A court has substantial discretion in deciding whether to grant a  
14 party's motion for certification. Brown v. Oneonta, 916 F. Supp.  
15 176, 180 (N.D.N.Y. 1996) rev'd in part on other grounds, 106 F.3d  
16 1125 (2nd Cir. 1997).

17 DISCUSSION

18 Abbott does not meet its burden to show that an interlocutory  
19 appeal is warranted. First, an appeal will not materially advance  
20 the ultimate termination of this litigation. On the contrary, an  
21 immediate appeal is likely to delay, rather than advance, the end  
22 of these cases. Dispositive motions are scheduled to be heard this  
23 summer, with trial calendared for February, 2011. Abbott suggests  
24 that the trial would not be materially delayed because the Ninth  
25 Circuit would hear an appeal on an expedited basis and might decide  
26 before the trial date. Abbott's assertions do not persuade the  
27 Court. As Plaintiffs correctly note, an interlocutory appeal could  
28 only materially advance the ultimate termination of this litigation

1 if the Ninth Circuit accepts the appeal and rules in favor of  
2 Abbott on all the above-mentioned issues. Further, at least with  
3 regard to GSK, resolution of these issues does not address all  
4 claims asserted against Abbott. Thus, litigation would  
5 nevertheless continue.

6 Second, Abbott does not establish a substantial ground for  
7 difference of opinion. As it did in its omnibus motion to dismiss,  
8 Abbott insists that Doe and Linkline control the outcome of this  
9 case. However, as explained further in the Court's Order on the  
10 motion to dismiss, neither of those cases addressed the antitrust  
11 theories proffered by Plaintiffs in their amended complaints.  
12 Abbott quotes a portion of Doe, which states, "However labeled,  
13 Abbott's conduct is the functional equivalent of the price squeeze  
14 the Court found unobjectionable in Linkline." 571 F.3d at 935.  
15 This statement is taken out of context. In the section preceding  
16 the language Abbott quotes, the Ninth Circuit stated:

17 Does try to distance themselves from Linkline on the  
18 footing that their claim is for monopoly leveraging, not  
19 price squeezing, and that Abbott provides products to  
consumers in both the booster and boosted markets whereas  
AT & T provided products in retail and wholesale markets.  
We understand the difference, but it is insubstantial.  
20 However labeled, Abbott's conduct is the functional  
equivalent of the price squeeze the Court found  
unobjectionable in Linkline.  
21

22 Id. The Court reads this discussion to address the Doe plaintiffs'  
23 attempt to distinguish monopoly leveraging from price squeezing,  
24 not to immunize Abbott from liability under any antitrust theory.  
25 The Ninth Circuit did not rule on the theories proffered by  
26 Plaintiffs here and, as a result, Doe does not apply.

27 Abbott also argues that the Court's prior orders demonstrate a  
28 substantial ground for difference of opinion. However, like Doe

1 and Linkline, those orders addressed different antitrust theories  
2 and positions taken by the parties at that time. Although  
3 Plaintiffs' claims arise from the same series of acts as those  
4 complained of in Doe, their allegations and theories materially  
5 differ.

6 Abbott vehemently disagrees with the Court's reading of  
7 various cases, including Trinko and MetroNet. However, Abbott's  
8 contrary reading of authority is not enough to create a substantial  
9 ground for difference of opinion justifying an interlocutory  
10 appeal.

11 CONCLUSION

12 For the foregoing reasons, the Court DENIES Abbott's motion  
13 for certification of an interlocutory appeal. (Case No. 07-05470,  
14 Docket No. 137; Case No. 07-05985, Docket No. 233; Case No. 07-  
15 06120, Docket No. 126; Case No. 07-05702, Docket No. 199.)  
16 Dispositive motions are scheduled to be filed on July 30, 2010,  
17 with a hearing on the motions set for September 30, 2010 at 2:00  
18 p.m.

19 IT IS SO ORDERED.

20  
21 Dated: June 1, 2010



22 CLAUDIA WILKEN  
United States District Judge

23  
24  
25  
26  
27  
28